No information is available on the clinical use of trametinib during breastfeeding. Because trametinib is 97% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is 3.9 to 4.8 days, and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during trametinib therapy and for 4 months after the last dose.
关于曲美替尼在母乳喂养期间的临床应用尚无可用信息。由于曲美替尼与血浆蛋白的结合率为97%，乳汁中的含量可能较低。然而，其半衰期为3.9至4.8天，可能会在婴儿体内蓄积。制造商建议在曲美替尼治疗期间及最后一剂后4个月内停止母乳喂养。
